Video

Dr. Carey on Treating Triple-Negative Breast Cancer

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Lisa A. Carey, MD, professor of medicine, Breast Cancer Research, University of North Carolina, medical director, UNC Breast Center, chief of Hematology/Oncology, physician-in-chief, UNC North Carolina Cancer Hospital, discusses treatment options and challenges in triple-negative breast cancer.

Carey says the main challenge in treating triple-negative breast cancer is that physicians are limited to chemotherapy outside of clinical trials. However, there are relatively low-toxicity chemotherapy regimens that are used in the treatment of these patients.

Triple-negative breast cancer tends to behave like other subsets where taxanes are effective, and it has been shown that platinum drugs are as effective as taxanes in the first-line setting, Carey says.

Even though treatment in the space is limited to chemotherapy, Carey says there are 4-5 agents that can be used for the treatment of triple-negative breast cancer.

<<<

View more from the 32nd Annual Miami Breast Cancer Conference

Related Videos
Ruth M. O’Regan, MD
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Sheldon M. Feldman, MD
Dana Zakalik, MD